MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.

Virtual Learning Series

As the most common inflammatory neurological disease in young adults, multiple sclerosis (MS) can lead to severe neurological disability throughout adult life. With the introduction of newer agents over the last ten years, clinicians now have more options for treating patients with MS. 

Neuromyelitis optica spectrum disorders (NMOSD) are another type of inflammatory disorders of the central nervous system. Considered an orphan disease, NMOSD is characterized by more severe attacks and less complete recovery than MS. Three monoclonal antibodies have been approved within the last year for patients with NMOSD, offering a greater range of treatment options for patients.

This program supports clinicians in optimizing the medical management of MS & NMOSD. Using real case examples from clinical practice, this program reviews common clinical scenarios and treatment options to ensure effective management of patients with MS throughout the disease continuum. This activity is supported by an independent educational grant from Roche Products Saudi Arabia.

Accredited Content

Guidelines